Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Diabetology & Metabolic SyndromeOpen Access

Orforglipron cuts body weight by ~8% and improves HbA1c versus placebo in obesity and T2DM.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does orforglipron improve weight and glycemic outcomes compared to placebo in adults with obesity and type 2 diabetes mellitus?

Population

3 RCTs pooling 2,505 adults with obesity and type 2 diabetes mellitus

Comparison

Orforglipron at doses ranging from 3 mg to 45 mg vs Placebo

Design

Meta-analysis

Key result

Orforglipron reduced body weight by up to 7.80% and HbA1c by up to 1.67% compared to placebo in adults with obesity and type 2 diabetes mellitus.

Authors

AEAhmed EmaraMEMohamed EmaraAMA Mansour

Discussion

Loading...

Member takes

Overview

Supports orforglipron as an oral option in obese T2DM; extends non-peptide GLP-1 agonist evidence.

Key Points

  • This study aims to assess the efficacy and safety of orforglipron in adults with obesity and type 2 diabetes mellitus through a meta-analysis.
  • Systematic review and meta-analysis of randomized controlled trials comparing orforglipron with placebo.
  • Inclusion of three randomized controlled trials with a total of 2,505 participants.
  • Use of random-effects models to determine mean differences and risk ratios.
  • Body weight reductions ranged from MD − 2.43% at 3 mg to MD − 7.80% at 24 mg.
  • HbA1c reductions varied from MD − 0.80% at 3 mg to MD − 1.67% at 45 mg.
  • Serious adverse events were similar between orforglipron and placebo groups, but treatment discontinuation due to adverse events was higher with orforglipron.

Study Design

Type

Meta-Analysis (n=2,505)

Blinding

Double-blind

Randomization

Randomized

Multicenter

Yes

Structured PICO

Does orforglipron improve weight and glycemic outcomes compared to placebo in adults with obesity and type 2 diabetes mellitus?

P
Population
2,505 adults (mean age 56.3 years, 47.5% female) with obesity and type 2 diabetes mellitus from 3 randomized controlled trials, followed for 10 to 17.5 months.
I
Intervention
Orforglipron (oral glucagon-like peptide-1 receptor agonist) at doses ranging from 3 mg to 45 mg
C
Comparator
Placebo
O
Outcome
Body weight, BMI, waist circumference, HbA1c, and fasting serum glucosesurrogate

Main Result

Mean Difference: -7.8

Orforglipron demonstrates dose-dependent efficacy in reducing body weight and improving glycemic control in patients with obesity and T2DM, though it is associated with higher rates of treatment discontinuation due to adverse events.

Limitations

  • Based on only three randomized controlled trials
  • Several key efficacy outcomes were rated as low certainty

Cite This Study

Emara et al. (2026) conducted a meta-analysis in Obesity and type 2 diabetes mellitus (n=2,505). Orforglipron vs. Placebo was evaluated on Percentage change from baseline in body weight (24 mg dose) (MD -7.80%). Orforglipron reduced body weight by up to 7.80% and HbA1c by up to 1.67% compared to placebo in adults with obesity and type 2 diabetes mellitus.

synapsesocial.com/papers/6a3f981b125782b61d865cdbhttps://doi.org/10.1186/s13098-026-02218-9
View Full Paper
Ask AI
Bookmark
Share